Methods and compositions for wound healing
US-2024139237-A1 · May 2, 2024 · US
Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
US10765670B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10765670-B2 |
| Application number | US-201815903662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2018 |
| Priority date | Oct 31, 2011 |
| Publication date | Sep 8, 2020 |
| Grant date | Sep 8, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.
First claim
Opening claim text (preview).
The invention claimed is: 1. Therapeutic substance combination product containing at least one connexin-blocking agent and one acetylcholinesterase inhibitor (AChEI), wherein said connexin-blocking agent is mefloquine and said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof, wherein the therapeutic substance combination product is for improving cognitive function in a patient suffering from Alzheimer's disease, Parkinson disease, vascular dementia or senile dementia. 2. A method for improving cognitive function in a patient suffering from Alzheimer's disease, Parkinson disease, vascular dementia or senile dementia, which comprises administering to the patient in need thereof a therapeutic substance combination product containing at least one connexin-blocking agent and an acetylcholinesterase inhibitor (AChEI), wherein said connexin-blocking agent is mefloquine and said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof. 3. A method of potentiating the effect of donepezil or a pharmaceutical salt thereof in a patient suffering from a cognitive disorder, which comprises coadministering a connexin-blocking agent with said donepezil or a pharmaceutical salt thereof to the patient, wherein said connexin-blocking agent is mefloquine, wherein the cognitive disorder is selected from the group consisting of Alzheimer's disease, Parkinson disease, vascular dementia and senile dementia. 4. The method according to claim 3 , wherein the donepezil or a pharmaceutical salt thereof and mefloquine are coadministered simultaneously as a single dosage. 5. The method according to claim 3 , wherein the donepezil or a pharmaceutical salt thereof and mefloquine are coadministered simultaneously as separate dosages. 6. The method according to claim 3 , wherein the donepezil or a pharmaceutical salt thereof and mefloquine are coadministered separately within 1 minute to 5 hours of each other. 7. The method according to claim 3 , wherein the donepezil or a pharmaceutical salt thereof and mefloquine are coadministered separately within 1 minute to 2 hours of each other.
Assignees
Inventors
Classifications
Cinchonan derivatives, e.g. quinine · CPC title
- A61K31/445Primary
Non condensed piperidines, e.g. piperocaine · CPC title
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10765670B2 cover?
- This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.
- Who is the assignee on this patent?
- Commissariat Energie Atomique
- What technology area does this patent fall under?
- Primary CPC classification A61K31/445. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).